Systemic Bio intends to open an exciting new growth market for 3D Systems in the pharmaceutical arena, creating a biotech revenue stream for the company that could approach $100 million annually over the next five years. Systemic Bio’s efforts will be supported by an initial $15 million seed investment from 3D Systems, which, given the maturity of the underlying materials and process technology, is envisioned to support them through the start-up phase, bridging them to a material revenue level and profitability. In addition, this approach could eventually reduce or even eliminate the need for animal testing as a precursor to full-scale human trials for new drug development. The ability to accurately simulate human response to an experimental drug in the laboratory, early in the development process, offers the potential to significantly reduce both the high costs and extended times required for pharmaceutical companies to bring a new drug to market. These proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with any desired drug compound to study drug metabolism and the effects on healthy or diseased tissue at the earliest stages of new pharmaceutical drug development. Systemic Bio will leverage 3D Systems’ breakthrough, production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells. ![]() Today, 3D Systems (NYSE:DDD) announced the formation of a new, wholly owned company called Systemic Bio ™, a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |